Background Cardiovascular disease is the leading cause of death worldwide. Although
many pharmacological agents exist, drug compliance and therapeutic goal achievement …

Statins have been proven to be effective in minimizing the risk of cardiovascular adverse
events, however, their effect on BP variability is debatable with respect to their significance …

Some studies have suggested the antihypertensive effects of statins, a class of lipid-lowering
agents, particularly in patients with hypertension. However, the evidence for the role of …

Hypertension in Mexico has a prevalence of 32% and is the second most widespread cause
of consultation in primary care. Only 40% of patients in treatment have a blood pressure (BP) …

Single risk factors, such as hypertension and dyslipidemia, can combine to exacerbate the
development and severity of cardiovascular disease. Treatment goals may be more …

This multicenter, randomized, double‐blind, parallel‐group phase III clinical trial aimed to
investigate the efficacy and safety of a rosuvastatin+ amlodipine combination compared with …

Various single‐pill combinations (SPCs) have been introduced to improve drug compliance
and clinical efficacy. However, there is a lack of real‐world evidence regarding the …

Hypertension and dyslipidemia are important risk factors for cardiovascular disease.
However, the clinical outcomes of fixed‐dose combination (FDC) versus free‐equivalent …

This study aimed to compare and evaluate the efficacy of the blood pressure (BP) control
and cholesterol‐lowering effects and safety of combination therapy with telmisartan …

Background Blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) are
important risk factors for cardiovascular (CV) diseases. Although treating these factors …